Sign in
Taking people in United StatesNo phase

COVID-19 Coagulopathy Extension Study

Key facts

Who runs it
University of Iowa
Where
Iowa City, United StatesSee the site
Trial code
Status
Recruiting
People taking part
180 people, planned
Started
21 Jan 2022
Planned end
31 Dec 2025
Type of study
Observational, 3 groups
Record updated
6 April 2025

Who can take part

Age
18 years to 99 years
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (8)Hide the full registry criteria

Who can take part

  • Subjects must meet all inclusion criteria in one of the following three categories:
  • Acute COVID-19; Hospital admission for management of symptoms related to COVID-19; Laboratory confirmed infection with SARS-CoV-2 by either PCR or antigen testing within 4 weeks of hospital admission; Age ≥18 years
  • Incidental COVID-19; Hospital admission for indications unrelated to COVID-19 who are incidentally found to have infection with SARS-CoV-2; Age ≥18 years
  • Acute influenza; Hospital admission for clinical management of symptoms related to influenza; Laboratory confirmed infection with influenza A or influenza B within 4 weeks of hospital admission; Negative testing for SARS-CoV-2; Age ≥18 years

Who cannot take part

  • History of a bleeding disorder
  • Active cancer
  • Current pregnancy
  • Prisoner

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • Covid-19

This trial is currently available in United States.

  • University of Iowa Health CareIowa City, United StatesContact: Katina WilsonTaking people

About the trial

What the trial wants to find out

At the University of Iowa, the investigators led a multicenter randomized clinical trial comparing standard prophylactic dose to intermediate dose enoxaparin in hospitalized patients with COVID-19 (NCT04360824). As part of an exploratory biomarker component of this trial, blood samples were collected from hospitalized COVID-19 patients at enrollment and weekly for up to 30 days of hospitalization. The pilot results, as well as reports from other groups, demonstrate increased potential for thrombin generation in the plasma of COVID-19 patients. In particular, in the COVID-19 patient cohort enhanced thrombin generation potential persisted for at least 30 days of hospitalization. The investigators now propose to explore the mechanistic roles of activation of blood cells (such as platelets and neutrophils) and products of cellular activation as mediators of enhanced thrombin generation in patients with COVID-19. The study design will be a longitudinal cohort study, which will allow for the determination of the time course of enhanced thrombin generation potential in relation to clinical outcomes and changes in markers of cellular activation in serial samples obtained from COVID-19 patients for up to 3 years after infection with SARS-CoV-2. This study may provide clues to why a subset of COVID-19 patients present with late thrombotic complications even after apparent recovery from SARS-CoV-2 infection. An ongoing question in the field relates to the comparative prothrombotic effects of acute COVID-19 versus incidental SARS-CoV-2 infection versus acute infection with influenza viruses. Therefore, we will include three categories of hospitalized patients in this study: (1) acute COVID-19, (2) incidental COVID-19, and (3) acute influenza A or B. This project has a strong scientific rationale with direct clinical implications, especially given the emergence of SARS-CoV-2 variants such as delta and omicron that may prolong the pandemic and/or cause surges of COVID-19 in the coming months.

The 3 groups in the trial

  • Acute COVID-19

    Hospital admission for management of symptoms related to COVID-19. Laboratory confirmed infection with SARS-CoV-2 by either PCR or antigen testing within 4 weeks of hospital admission. Age ≥18 years.

  • Incidental COVID-19

    Hospital admission for indications unrelated to COVID-19 who are incidentally found to have infection with SARS-CoV-2. Age ≥18 years.

  • Acute influenza

    Hospital admission for clinical management of symptoms related to influenza. Laboratory confirmed infection with influenza A or influenza B within 4 weeks of hospital admission. Negative testing for SARS-CoV-2. Age ≥18 years.

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Cellular Effects of SARS-CoV-2 in Mediating Thrombotic Susceptibility
Criteria questions
Built from NCT05334615, who can take part
Record updated
6 April 2025